121 related articles for article (PubMed ID: 24601193)
1. The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer.
Ali HQ; Mahdi NK; Al-Jowher MH
J Pak Med Assoc; 2013 Sep; 63(9):1138-41. PubMed ID: 24601193
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
Nisman B; Maimon O; Allweis T; Kadouri L; Maly B; Hamburger T; Peretz T
Anticancer Res; 2013 Jan; 33(1):293-9. PubMed ID: 23267160
[TBL] [Abstract][Full Text] [Related]
3. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
5. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
7. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
Martín A; Corte MD; Alvarez AM; Rodriguez JC; Andicoechea A; Bongera M; Junquera S; Pidal D; Allende T; Muñiz JL; Vizoso F
Anticancer Res; 2006; 26(5B):3965-71. PubMed ID: 17094428
[TBL] [Abstract][Full Text] [Related]
9. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
10. [Application of serum proteomic mass spectrum analysis in breast cancer].
Ying MG; Chen Q; Ye YB; Chen HJ; Chen X; Zheng HY; Wu F
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):698-702. PubMed ID: 21122387
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers.
Brouckaert O; Laenen A; Wildiers H; Floris G; Moerman P; Van Limbergen E; Vergote I; Billen J; Christiaens MR; Neven P
Breast; 2013 Jun; 22(3):254-62. PubMed ID: 23566558
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of CA15.3 in 7942 patients with operable breast cancer.
Sandri MT; Salvatici M; Botteri E; Passerini R; Zorzino L; Rotmensz N; Luini A; Mauro C; Bagnardi V; Cassatella MC; Bottari F; Casadio C; Colleoni M
Breast Cancer Res Treat; 2012 Feb; 132(1):317-26. PubMed ID: 22065291
[TBL] [Abstract][Full Text] [Related]
13. The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status.
Hashim ZM
Int J Immunopathol Pharmacol; 2014; 27(1):45-51. PubMed ID: 24674678
[TBL] [Abstract][Full Text] [Related]
14. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
15. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
16. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
[TBL] [Abstract][Full Text] [Related]
18. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer?
Velaiutham S; Taib NA; Ng KL; Yoong BK; Yip CH
Asian Pac J Cancer Prev; 2008; 9(3):445-8. PubMed ID: 18990019
[TBL] [Abstract][Full Text] [Related]
19. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
20. Plasma free serotonin as a marker for early detection of breast cancer recurrence.
Fröbe A; Čičin-Šain L; Jones G; Soldič Ž; Lukač J; Bolanča A; Kusič Z
Anticancer Res; 2014 Mar; 34(3):1167-9. PubMed ID: 24596355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
